Thank you for giving me the chance to have a mammogram done. – Conchita C.

Words cannot express my appreciation!! -Beth Finamore-Neff

Early detection programs has played a big role – KARM

UCSF has shaped the human service foundational experience – Ms. Jacqueline G. McRae-Mitchell

We are so appreciative of Mercedes and all her staff and helpers. – Mayor Dale Perdue and Staff

(855) 622-6237

A cancer treatment set to  was approved by the U.S. Food and Drug Administration earlier this month. Hopefully it will give women diagnosed with HER2-low breast cancer extended survival rates.

The groundbreaking new drug, Enhertu, deleoped by AstraZeneca, was given approval for use in women with unresectable or metastatic HER2-low breast cancer.

So what should you know about this treatment?

Enhertu is a targeted cancer treatment meaning it attacks cancer cells without damaging healthy cells. It is used when the cancer is not removable with surgery.
Enhertu is a targeted therapy made up of three parts:
– fam-trastuzumab: an anti-HER2 medicine that has the same basic structure as Herceptin (chemical name: trastuzumab)
– a topoisomerase I inhibitor chemotherapy called DXd: topoisomerase I inhibitors work by interfering with a cancer cell’s ability to replicate
– a compound that links the fam-trastuzumab molecule to the topoisomerase I inhibitor chemotherapy molecule

What are the findings of Enhertu trials?

According to the New England Journal of Medicine Enhertu “resulted in significantly longer progression-free and overall survival than the physician’s choice of chemotherapy.”

 researchers recruited 557 patients with metastatic breast cancer who had the HER2-low subtype. Two-thirds of the patients received Enhertu; the others were treated with their doctor’s preferred treatment.

The patients that received Enhertu, had tumor growth stopped for 10 month. Those who received chemotherapy, had tumor growth stop on average for five months. Enhertu patients survived for 23.9 months, while those that recieved chemotherapy survived 16.8 months.



New england Journal of medicine: